Suppression of neointimal hyperplasia by targeted blockade of the EGFR signaling pathway as shown in preclinical models with distinct pathophysiologies (Chan et al. 2003; Nicholl et al. 2005; Trieu et al. 2000) might serve as a possible therapeutic option for children with cyanotic heart disease requiring placement of SP shunts, specifically in the smallest size shunts given their high risk for obstruction (Wells et al. 2005). Here, EGFR is linked to heart disorder.